Categories: Invest

Should you invest in Gilead Sciences after guiding FY2021 earnings above estimates?

On Thursday, Gilead Sciences Inc. (NASDAQ:GILD) shares edged lower by 2.3% in the after-hours session despite posting solid fiscal Q3 results. The company announced its most recent quarterly results after markets closed, beating analyst expectations on revenue and earnings. Gilead also issued a better-than-expected FY2021 EPS guidance.

The company posted FQ3 non-GAAP earnings per share of $2.65, beating the consensus analyst estimate of $1.78. On the other hand, its GAAP EPS of $2.05 outperformed the expectation of $1.37, while revenue for the quarter increased by 13.1% from the same quarter in 2020 to $7.42 billion, $1.08 billion ahead of estimates.


Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

The company also raised its earnings guidance to about $7.90-$8.10 from $6.90-$7.25, previously, ahead of the average Street forecast of $7.25.

Is Gilead undervalued?

From an investment perspective, Gilead shares trade at an exciting forward P/E ratio of 9.97, making the stock an attractive option for value investors.

However, with analysts expecting earnings per share to fall by nearly 98% this year before rising at an average annual rate of just 1.32% over the next five years, growth investors could opt for alternatives.

Gilead is substantially underperforming the S&P 500 Index based on its YTD gain of just 12%. Therefore, there is a lot of room left to catch up.

Source – TradingView

Technically, Gilead shares seem to be trading within a descending channel formation in the intraday chart. However, the stock has recently bounced off the trendline support to recover from oversold conditions.

Therefore, with shares still far from reaching overbought conditions, the current rebound could continue, pushing the stock towards the 100-day moving average.

Investors could target profits at about $68.77 or higher at $71.70, while $63.91 and $61.52 are crucial support zones.

Buy the pullback?

In summary, Gilead Sciences shares trade at a compelling forward P/E, making it an ideal opportunity for value investors.

Therefore, given the recent price movement, the post-earnings pullback could be an opportunity to buy.

Where to buy right now

To invest simply and easily, users need a low-fee broker with a track record of reliability. The following brokers are highly rated, recognised worldwide, and safe to use:

  1. Etoro, trusted by over 13m users worldwide. Register here >
  2. Capital.com, simple, easy to use and regulated. Register here >
admin

Share
Published by
admin

Recent Posts

Is there a way for the crypto sector to avoid Bitcoin’s halving-related bear markets?

There is good reason to be afraid. Previous down markets have seen declines in excess…

2 years ago

UPS and FedEx are good dividend stocks, but which should you take?

United Parcel Service, Inc. (NYSE:UPS) and FedEx Corporation (NYSE:FDX) are two robust logistics companies. Both…

2 years ago

Bitfarms sold 3K Bitcoin as part of strategy to improve liquidity and pay debts

Canadian crypto mining firm Bitfarms sold roughly $62 million worth of Bitcoin (BTC) in June,…

2 years ago

This biotech stock is up 100% on Tuesday: here’s the catalyst

Invezz does not provide financial advice. Our aim is to simplify information about investing, enabling…

2 years ago

Japanese film studio announces the production of a series based on crypto

Noma, a Japanese film studio, has announced that it is producing three feature films that…

2 years ago

Bitcoin price taps 5-day highs as Shiba Inu leads altcoin gains

Bitcoin (BTC) saw continued strength on June 21 as Wall Street trading opened with a…

2 years ago